Temporal evolution of antiparkinsonian drug prescription over 17 years: a real-world data analysis of Korean patients with Parkinson’s disease
Neurological Sciences · 2026-05 · 47 (5)
DOI: 10.1007/s10072-026-08962-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Sciences, online erschienen am 06.04.2026. Verfasst von Bora Yoon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Parkinson Disease, Antiparkinson Agents, Levodopa, Practice Patterns, Physicians'. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Evidence-based guidelines guide Parkinson’s disease (PD) management, but real-world prescription patterns may differ owing to patient and practice variability. Large-scale, longitudinal data can clarify how antiparkinsonian drugs are prescribed in practice. METHODS: We analyzed nationwide claims from the Korean National Health Insurance Service between 2002 and 2019. Patients with PD were identified using ICD-10 G20 plus V124 code. Initial prescriptions, combination regimens, and dosage adjustments were examined in 160,476 patients. For 64,779 patients receiving levodopa or dopamine-agonist (DA) monotherapy with complete 3-year follow-up, levodopa-equivalent daily dose (LEDD) was calculated quarterly. Group-based trajectory modeling identified longitudinal LEDD patterns, and Sankey plots visualized prescription transitions. RESULTS: Monotherapy was the initial treatment in 66.3% of patients, predominantly levodopa, whose use increased with age. DA monotherapy decreased with age, and DA prescriptions stabilized around 10% after 2010. In the polytherapy group (33.7%), > 90% received levodopa- or DA-based combinations. The mean initial LEDD was approximately 200 mg/day across age groups. Four LEDD trajectories were identified: consistently high (5%), moderately increasing (17%), low-to-moderate stable (29%), and low stable (49%). From 2003–2010 to 2011–2019, the low-stable group decreased (56% → 42%), whereas moderate-increasing and low-to-moderate stable groups increased (14% → 20% and 24% → 32%). Sankey plots indicated that medication adjustments occurred mainly during the first 3–4 quarters after initiation, differing by trajectory group. CONCLUSIONS: This real-world analysis demonstrates stable dominance of levodopa, age-dependent DA use, and temporal shifts toward earlier, active titration. Distinct LEDD trajectories and early adjustment patterns underscore the need for individualized pharmacotherapy strategies in PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Medical Informatics and Statistics, Asan Medical Center, Ulsan University College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Republic of Korea. hello.hello.hj@gmail.com.
ORCID-Profile: Bora Yoon, Hwa Jung Kim
Zitieren
APA
Yoon, B., & Kim, H. J. (2026). Temporal evolution of antiparkinsonian drug prescription over 17 years: a real-world data analysis of Korean patients with Parkinson’s disease. Neurological Sciences, 47(5). https://doi.org/10.1007/s10072-026-08962-0
Vancouver
Yoon B, Kim HJ. Temporal evolution of antiparkinsonian drug prescription over 17 years: a real-world data analysis of Korean patients with Parkinson’s disease. Neurological Sciences. 2026;47(5). doi:10.1007/s10072-026-08962-0
BibTeX
@article{Yoon2026,
author = {Yoon, Bora and Kim, Hwa Jung},
title = {Temporal evolution of antiparkinsonian drug prescription over 17 years: a real-world data analysis of Korean patients with Parkinson’s disease},
journal = {Neurological Sciences},
year = {2026},
volume = {47},
number = {5},
doi = {10.1007/s10072-026-08962-0}
}
EUVIMED